With the accumulation of human SCLC tumors, a “real-world” study identified three potential genetic subtypes: a cohort without TP53/RB1 alteration, a cohort with STK11 mutation, and a cohort that may transform from NSCLC with typical oncogenic driver mutations [62]. This evidence concerns the gene STK11 and non-small cell lung carcinoma.